Announcement • Jun 30
Yixintang Pharmaceutical Group Co., Ltd. to Report First Half, 2026 Results on Aug 27, 2026 Yixintang Pharmaceutical Group Co., Ltd. announced that they will report first half, 2026 results on Aug 27, 2026 Declared Dividend • May 27
Dividend of CN¥0.20 announced Shareholders will receive a dividend of CN¥0.20. Ex-date: 29th May 2026 Payment date: 29th May 2026 Dividend yield will be 3.5%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (82% earnings payout ratio) and cash flows (14% cash payout ratio). The dividend has increased by an average of 4.8% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 112% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Board Change • May 20
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Chao Long was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Apr 29
Yixintang Pharmaceutical Group Co., Ltd., Annual General Meeting, May 20, 2026 Yixintang Pharmaceutical Group Co., Ltd., Annual General Meeting, May 20, 2026, at 14:00 China Standard Time. Location: No. 1, Hongxiang Road, Economic and Technological Development Zone, Kunming, Yunnan China Announcement • Mar 31
Yixintang Pharmaceutical Group Co., Ltd. to Report Q1, 2026 Results on Apr 29, 2026 Yixintang Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026 Announcement • Mar 23
Yixintang Pharmaceutical Group Co., Ltd.(XSEC:002727) dropped from FTSE All-World Index (USD) Yixintang Pharmaceutical Group Co., Ltd.(XSEC:002727) dropped from FTSE All-World Index (USD) Announcement • Dec 31
Yixintang Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2025 Results on Apr 29, 2026 Yixintang Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2025 results on Apr 29, 2026 Announcement • Nov 15
Yixintang Pharmaceutical Group Co., Ltd. Announces Board Appointments Yixintang Pharmaceutical Group Co., Ltd. held its 3rd Extraordinary General Meeting of 2025 on 13 November 2025, approved the appointment of Jiang Ning, non-independent director, Zhang Yong, non-independent director, Ruan Aixiang, non-independent director, Long Chao, independent director, Liu Lifang, independent director, Shi Qian, independent director. Announcement • Sep 30
Yixintang Pharmaceutical Group Co., Ltd. to Report Q3, 2025 Results on Oct 31, 2025 Yixintang Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2025 results on Oct 31, 2025 Announcement • Sep 18
Yixintang Pharmaceutical Group Co., Ltd. Approves Interim Cash Dividend for the Year 2025 Yixintang Pharmaceutical Group Co., Ltd. at its 2nd Extraordinary General Meeting of 2025 held on 16 September 2025, approved 2025 interim Cash dividend/10 shares (tax included) of CNY 2.00000000. Announcement • Sep 02
Yixintang Pharmaceutical Group Co., Ltd. Proposes Interim Profit Distribution Plan for 2025 Yixintang Pharmaceutical Group Co., Ltd. at 2nd Extraordinary General Meeting of 2025 to be held on September 16, 2025 proposed interim profit distribution plan for 2025. For the period, the company reported Cash dividend/10 shares (tax included): CNY2.00000000. Announcement • Jul 02
Yixintang Pharmaceutical Group Co., Ltd. to Report First Half, 2025 Results on Aug 30, 2025 Yixintang Pharmaceutical Group Co., Ltd. announced that they will report first half, 2025 results on Aug 30, 2025 Announcement • Apr 28
Yixintang Pharmaceutical Group Co., Ltd., Annual General Meeting, May 21, 2025 Yixintang Pharmaceutical Group Co., Ltd., Annual General Meeting, May 21, 2025, at 14:00 China Standard Time. Location: No. 1, Hongxiang Road, Economic and Technological Development Zone, Kunming, Yunnan China Announcement • Mar 31
Yixintang Pharmaceutical Group Co., Ltd. to Report Q1, 2025 Results on Apr 28, 2025 Yixintang Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2025 results on Apr 28, 2025 Announcement • Feb 12
Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727) announces an Equity Buyback for CNY 150 million worth of its shares. Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727) announces a share repurchase program. Under the program, the company will repurchase up to CNY 150 million worth of its A shares. The shares will be repurchased at no more than CNY 19.02 per share. The purpose of the program is to maintain the value of the company and protect the interests of shareholders. The program will be funded from company's own funds and special loan funds for stock repurchase. The authorization will be valid for 3 months. Announcement • Dec 31
Yixintang Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2024 Results on Apr 28, 2025 Yixintang Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2024 results on Apr 28, 2025 Reported Earnings • Oct 31
Third quarter 2024 earnings released: EPS: CN¥0.018 (vs CN¥0.30 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.018 (down from CN¥0.30 in 3Q 2023). Revenue: CN¥4.28b (up 3.6% from 3Q 2023). Net income: CN¥10.6m (down 94% from 3Q 2023). Profit margin: 0.2% (down from 4.4% in 3Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has fallen by 26% per year whereas the company’s share price has fallen by 28% per year. Announcement • Sep 30
Yixintang Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024 Yixintang Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥13.57, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 12x in the Consumer Retailing industry in China. Total loss to shareholders of 53% over the past three years. Reported Earnings • Aug 31
Second quarter 2024 earnings released: EPS: CN¥0.067 (vs CN¥0.45 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.067 (down from CN¥0.45 in 2Q 2023). Revenue: CN¥4.21b (flat on 2Q 2023). Net income: CN¥40.0m (down 85% from 2Q 2023). Profit margin: 1.0% (down from 6.3% in 2Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings. Announcement • Jul 26
Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727) commences an Equity Buyback Plan for CNY 150 million worth of its shares, under the authorization approved on July 2, 2024. Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727) commences share repurchases on July 24, 2024, under the program mandated by shareholders in the Annual General Meeting held on July 2, 2024. As per the mandate, the company is authorized to repurchase up to CNY 150 million worth of its shares. The shares will be repurchased at no more than CNY 30.63 per share. The purpose of the program is to cancel and reduce registered capital. The program will be funded from company's own funds. The authorization will be valid for 12 months. Buy Or Sell Opportunity • Jul 05
Now 20% overvalued Over the last 90 days, the stock has fallen 23% to CN¥14.84. The fair value is estimated to be CN¥12.34, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has declined by 5.9%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 23% per annum over the same time period. Announcement • Jun 29
Yixintang Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024 Yixintang Pharmaceutical Group Co., Ltd. announced that they will report first half, 2024 results on Aug 31, 2024 Declared Dividend • May 26
Dividend of CN¥0.40 announced Dividend of CN¥0.40 is the same as last year. Ex-date: 30th May 2024 Payment date: 30th May 2024 Dividend yield will be 1.8%, which is about the same as the industry average. Sustainability & Growth Dividend is well covered by both earnings (43% earnings payout ratio) and cash flows (12% cash payout ratio). The dividend has increased by an average of 3.2% per year over the past 9 years and payments have been stable during that time. EPS is expected to grow by 90% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • May 25
Yixintang Pharmaceutical Group Co., Ltd. Announces Dividend Implementation for 2023, Payable on 30 May 2024 Yixintang Pharmaceutical Group Co., Ltd. announced 2023 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included): CNY 4.00000000. Record date: 29 May 2024; Ex-date: 30 May 2024; Payment date: 30 May 2024. Announcement • Apr 29
Yixintang Pharmaceutical Group Co., Ltd., Annual General Meeting, May 21, 2024 Yixintang Pharmaceutical Group Co., Ltd., Annual General Meeting, May 21, 2024, at 14:00 China Standard Time. Location: No. 1, Hongxiang Road, Economic and Technological Development Zone, Kunming, Yunnan China Reported Earnings • Apr 27
First quarter 2024 earnings released: EPS: CN¥0.41 (vs CN¥0.40 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.41 (up from CN¥0.40 in 1Q 2023). Revenue: CN¥5.10b (up 15% from 1Q 2023). Net income: CN¥241.9m (up 1.0% from 1Q 2023). Profit margin: 4.7% (down from 5.4% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings. Announcement • Mar 30
Yixintang Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024 Yixintang Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2024 results on Apr 27, 2024 Reported Earnings • Mar 19
Full year 2023 earnings released: EPS: CN¥0.92 (vs CN¥1.70 in FY 2022) Full year 2023 results: EPS: CN¥0.92 (down from CN¥1.70 in FY 2022). Revenue: CN¥17.4b (flat on FY 2022). Net income: CN¥549.4m (down 46% from FY 2022). Profit margin: 3.2% (down from 5.8% in FY 2022). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings. New Risk • Mar 19
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 3.2% Last year net profit margin: 5.8% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (3.2% net profit margin). Buy Or Sell Opportunity • Jan 30
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 14% to CN¥18.94. The fair value is estimated to be CN¥23.96, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 8.8%. Revenue is forecast to grow by 33% in 2 years. Earnings are forecast to grow by 39% in the next 2 years. Announcement • Dec 30
Yixintang Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024 Yixintang Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2023 results on Apr 27, 2024 Reported Earnings • Nov 01
Third quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.44 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.30 (down from CN¥0.44 in 3Q 2022). Revenue: CN¥4.14b (up 1.9% from 3Q 2022). Net income: CN¥181.3m (down 30% from 3Q 2022). Profit margin: 4.4% (down from 6.4% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 22
Second quarter 2023 earnings released: EPS: CN¥0.45 (vs CN¥0.40 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.45 (up from CN¥0.40 in 2Q 2022). Revenue: CN¥4.24b (up 6.8% from 2Q 2022). Net income: CN¥265.1m (up 11% from 2Q 2022). Profit margin: 6.3% (up from 6.0% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Announcement • May 20
Yixintang Pharmaceutical Group Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 26 May 2023 Yixintang Pharmaceutical Group Co., Ltd. announced final profit distribution plan to be implemented on A shares as cash dividend per ten shares (tax included) of CNY 4.00000000 for the year 2022, payable on 26 May 2023. Record date is 25 May 2023. Ex-date is 26 May 2023. Announcement • May 18
Yixintang Pharmaceutical Group Co., Ltd. Approves Cash Dividend for the Year 2022 Yixintang Pharmaceutical Group Co., Ltd. approved Cash dividend/10 shares (tax included) is CNY 4.00000000 for the year 2022 at its Annual General Meeting of 2022 held on 16 May 2023. Reported Earnings • Mar 18
Full year 2022 earnings released: EPS: CN¥1.70 (vs CN¥1.56 in FY 2021) Full year 2022 results: EPS: CN¥1.70 (up from CN¥1.56 in FY 2021). Revenue: CN¥17.4b (up 20% from FY 2021). Net income: CN¥1.01b (up 9.5% from FY 2021). Profit margin: 5.8% (down from 6.3% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Dec 04
Investor sentiment improved over the past week After last week's 21% share price gain to CN¥37.25, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 25x in the Consumer Retailing industry in China. Total returns to shareholders of 74% over the past three years. Valuation Update With 7 Day Price Move • Nov 18
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥35.60, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 25x in the Consumer Retailing industry in China. Total returns to shareholders of 59% over the past three years. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Executive Director Yong Zhang was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Oct 28
Third quarter 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.41 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.44 (up from CN¥0.41 in 3Q 2021). Revenue: CN¥4.06b (up 6.9% from 3Q 2021). Net income: CN¥259.1m (up 8.0% from 3Q 2021). Profit margin: 6.4% (up from 6.3% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 19
Second quarter 2022 earnings released: EPS: CN¥0.40 (vs CN¥0.45 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.40 (down from CN¥0.45 in 2Q 2021). Revenue: CN¥3.97b (up 21% from 2Q 2021). Net income: CN¥238.9m (down 9.3% from 2Q 2021). Profit margin: 6.0% (down from 8.0% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 16%, compared to a 17% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jul 21
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥25.80, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 24x in the Consumer Retailing industry in China. Total returns to shareholders of 15% over the past three years. Reported Earnings • May 02
First quarter 2022 earnings released: EPS: CN¥0.30 (vs CN¥0.44 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.30 (down from CN¥0.44 in 1Q 2021). Revenue: CN¥4.00b (up 17% from 1Q 2021). Net income: CN¥179.4m (down 31% from 1Q 2021). Profit margin: 4.5% (down from 7.6% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 20%, compared to a 16% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Board Change • Apr 27
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Non-Independent Director Zhang Yong was the last director to join the board, commencing their role in 2019. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Mar 16
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: EPS: CN¥1.56 (up from CN¥1.38 in FY 2020). Revenue: CN¥14.6b (up 15% from FY 2020). Net income: CN¥921.5m (up 17% from FY 2020). Profit margin: 6.3% (up from 6.2% in FY 2020). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.3%. Over the next year, revenue is forecast to grow 21%, compared to a 18% growth forecast for the retail industry in China. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Buying Opportunity • Feb 23
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 19%. The fair value is estimated to be CN¥36.68, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% per annum over the last 3 years. Earnings per share has grown by 20% per annum over the last 3 years. Valuation Update With 7 Day Price Move • Dec 10
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥39.10, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 23x in the Consumer Retailing industry in China. Total returns to shareholders of 81% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥36.46 per share. Reported Earnings • Oct 31
Third quarter 2021 earnings released: EPS CN¥0.41 (vs CN¥0.33 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥3.80b (up 18% from 3Q 2020). Net income: CN¥240.0m (up 28% from 3Q 2020). Profit margin: 6.3% (up from 5.9% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Reported Earnings • Jul 25
Second quarter 2021 earnings released: EPS CN¥0.45 (vs CN¥0.37 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥3.27b (up 11% from 2Q 2020). Net income: CN¥263.2m (up 24% from 2Q 2020). Profit margin: 8.0% (up from 7.2% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 30
First quarter 2021 earnings released: EPS CN¥0.44 (vs CN¥0.36 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥3.43b (up 11% from 1Q 2020). Net income: CN¥260.6m (up 27% from 1Q 2020). Profit margin: 7.6% (up from 6.6% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Mar 22
Investor sentiment improved over the past week After last week's 20% share price gain to CN¥46.98, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 27x in the Consumer Retailing industry in China. Total returns to shareholders of 84% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥25.66 per share. Reported Earnings • Mar 16
Full year 2020 earnings released: EPS CN¥1.38 (vs CN¥1.06 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥12.7b (up 21% from FY 2019). Net income: CN¥790.0m (up 31% from FY 2019). Profit margin: 6.2% (up from 5.8% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 13% per year. Reported Earnings • Feb 09
Full year 2020 earnings released: EPS CN¥1.38 (vs CN¥1.06 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥12.7b (up 21% from FY 2019). Net income: CN¥790.3m (up 31% from FY 2019). Profit margin: 6.2% (up from 5.8% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Feb 09
New 90-day high: CN¥46.68 The company is up 27% from its price of CN¥36.80 on 11 November 2020. The Chinese market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥39.87 per share. Analyst Estimate Surprise Post Earnings • Feb 09
Revenue beats expectations Revenue exceeded analyst estimates by 0.3%. Over the next year, revenue is forecast to grow 19%, compared to a 22% growth forecast for the Consumer Retailing industry in China. Valuation Update With 7 Day Price Move • Jan 13
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥38.18, the stock is trading at a trailing P/E ratio of 29.9x, up from the previous P/E ratio of 25.4x. This compares to an average P/E of 34x in the Consumer Retailing industry in China. Total returns to shareholders over the past three years are 92%. Is New 90 Day High Low • Jan 07
New 90-day low: CN¥32.38 The company is down 18% from its price of CN¥39.33 on 09 October 2020. The Chinese market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥25.31 per share. Is New 90 Day High Low • Dec 23
New 90-day low: CN¥34.00 The company is down 16% from its price of CN¥40.35 on 25 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥25.31 per share. Valuation Update With 7 Day Price Move • Dec 23
Investor sentiment deteriorated over the past week After last week's 15% share price decline to CN¥34.00, the stock is trading at a trailing P/E ratio of 26.7x, down from the previous P/E ratio of 31.4x. This compares to an average P/E of 35x in the Consumer Retailing industry in China. Total returns to shareholders over the past three years are 80%. Is New 90 Day High Low • Dec 04
New 90-day high: CN¥42.23 The company is up 1.0% from its price of CN¥41.90 on 04 September 2020. The Chinese market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥21.73 per share. Reported Earnings • Oct 29
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥724.0m, up 23% from the prior year. Total revenue was CN¥12.1b over the last 12 months, up 18% from the prior year. 
